LYCOS RETRIEVER 
Immunex Corporation
built 134 days ago
Immunex Corporation is a biopharmaceutical company that develops, manufacturers, and markets therapeutic products for the treatment of cancer, infectious diseases, and autoimmune disorders. The company more than doubled its revenue base between 1992 and 1993 as a result of a merger with Lederle pharmaceutical units of American Cyanamid Company. However, in the mid-1990s, Immunex was still trying to achieve profitability after investing heavily in research and development since its inception in 1981. Immunex is best associated with the development of products such as Enbrel, used in the treatment of rheumatoid arthritis; Novantrone, used to treat acute nonlymphocytic leukemia and pain associated with prostate cancer; and Leukine, for use in bone marrow transplant patients. In July 2002, Immunex was bought by Amgen Inc., the world's largest biotechnology company.
Source:
Immunex Corporation and Wyeth-Ayerst Laboratories, a division of American Home Products Corporation, market ENBREL in North America. Other AHP affiliates market ENBREL outside of North America. Immunex manufactures ENBREL. Additional information about ENBREL, including full prescribing information, can be found on the company-sponsored Web site at (www.enbrel.com) or by calling toll-free 888-4ENBREL (888-436-2735).
Source:
Immunex Corporation and Wyeth-Ayerst Laboratories will market Enbrel in North America while other Wyeth-Ayerst affiliates will market the drug outside North America. The drug is expected on pharmacy shelves within days. A prescription is required to obtain the drug. The cost of Enbrel will be $220 per week ($110 per vial of Enbrel).
Source:
Immunex Corporation was acquired by Amgen, Inc. on July 15, 2002. Immunex Corporation develops products and therapeutics for the treatment of rheumatoid arthritis, asthma, and other inflammatory diseases, as well as cancer and cardiovascular diseases. It markets three products treating multiple indications, Enbrel®, Novantrone®, and Thioplex® in the United States. Enbrel® is a soluble Tumor Necrosis Factor (TNF) receptor that inhibits the binding of TNF to TNF cell surface receptors, resulting in a significant reduction in inflammatory activity in rheumatoid arthritis. Novantrone® is used to treat some cancers with a molecular change that results in less damage to the heart. Thioplex® is approved for the palliative treatment of a variety of tumor types.
Source:
American Home Products Corporation owns a majority interest in Immunex. AHPC is one of the world's largest research-based pharmaceutical and health care products companies and is a leading developer, manufacturer and marketer of prescription drugs and over-the-counter medications. It is ... a leader in vaccines, biotechnology, agricultural products and animal health care.
Source:
HuMax-IL15 is a high-affinity, fully human antibody against Interleukin-15 (IL-15) being developed by Genmab and Immunex Corporation. IL-15 is a cytokine, an immune system signaling molecule, that appears early in the cascade of events that ultimately lead to inflammatory disease. IL-15 is a particularly interesting disease target because it is involved in several steps of the inflammation cycle. IL-15 induces both the production of TNF-alpha, another cytokine that has been shown to play a pivotal role in inflammation, as well as the recruitment of inflammatory T cells. These T cells in turn promote the production of more IL-15, and the cycle escalates.
Source:
MORE ABOUT
Immunex Corporation